Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
Research output: Contribution to journal › Article › peer-review
198Scopus
citations
Fingerprint
Dive into the research topics of 'Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial'. Together they form a unique fingerprint.